164 related articles for article (PubMed ID: 22506770)
21. Identification of sibling species of the bryozoan Bugula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "Candidatus Endobugula sertula".
Davidson SK; Haygood MG
Biol Bull; 1999 Jun; 196(3):273-80. PubMed ID: 10390826
[TBL] [Abstract][Full Text] [Related]
22. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.
May WS; Sharkis SJ; Esa AH; Gebbia V; Kraft AS; Pettit GR; Sensenbrenner LL
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8483-7. PubMed ID: 3317410
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
24. Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.
Sun MK; Alkon DL
CNS Drug Rev; 2006; 12(1):1-8. PubMed ID: 16834754
[TBL] [Abstract][Full Text] [Related]
25. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
26. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into the interactions of phorbol ester and bryostatin complexed with protein kinase C: a comparative molecular dynamics simulation study.
Thangsunan P; Tateing S; Hannongbua S; Suree N
J Biomol Struct Dyn; 2016 Jul; 34(7):1561-75. PubMed ID: 26292580
[TBL] [Abstract][Full Text] [Related]
28. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
29. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
[TBL] [Abstract][Full Text] [Related]
31. Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina.
Davidson SK; Allen SW; Lim GE; Anderson CM; Haygood MG
Appl Environ Microbiol; 2001 Oct; 67(10):4531-7. PubMed ID: 11571152
[TBL] [Abstract][Full Text] [Related]
32. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.
Dale IL; Bradshaw TD; Gescher A; Pettit GR
Cancer Res; 1989 Jun; 49(12):3242-5. PubMed ID: 2720677
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase C activator bryostatin-1 modulates proteasome function.
Khan TK; Nelson TJ
J Cell Biochem; 2018 Aug; 119(8):6894-6904. PubMed ID: 29693282
[TBL] [Abstract][Full Text] [Related]
34. Binding of [3H]bryostatin 4 to protein kinase C.
Lewin NE; Dell'Aquila ML; Pettit GR; Blumberg PM; Warren BS
Biochem Pharmacol; 1992 May; 43(9):2007-14. PubMed ID: 1596288
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
36. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes.
Kazanietz MG; Lewin NE; Gao F; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Aug; 46(2):374-9. PubMed ID: 8078499
[TBL] [Abstract][Full Text] [Related]
37. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.
Hood KA; Bäckström BT; West LM; Northcote PT; Berridge MV; Miller JH
Anticancer Drug Des; 2001; 16(2-3):155-66. PubMed ID: 11962513
[TBL] [Abstract][Full Text] [Related]
38. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
39. Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
Wender PA; Lippa B; Park CM; Irie K; Nakahara A; Ohigashi H
Bioorg Med Chem Lett; 1999 Jun; 9(12):1687-90. PubMed ID: 10397502
[TBL] [Abstract][Full Text] [Related]
40. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
